Unknown

Dataset Information

0

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.

ABSTRACT:

SUBMITTER: Lew TE 

PROVIDER: S-EPMC10955641 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
| S-EPMC11451299 | biostudies-literature
Unknown Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort.
| S-EPMC12275189 | biostudies-literature
Unknown Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
| S-EPMC9642790 | biostudies-literature
Unknown Ibrutinib induces durable remissions in treatment-naive patients with CLL and 17p deletion and/or TP53 mutations.
| S-EPMC8832441 | biostudies-literature
Unknown Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
| S-EPMC9412011 | biostudies-literature
Genomics CLL-Venetoclax
| PRJEB24344 | ENA
Unknown Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial.
| S-EPMC11451378 | biostudies-literature
Unknown Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
| S-EPMC9710452 | biostudies-literature
Unknown Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL.
| S-EPMC6981459 | biostudies-literature
Unknown Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center.
| S-EPMC12665162 | biostudies-literature